Published in N Engl J Med on August 09, 2012
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med (2015) 2.10
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol (2013) 2.07
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol (2013) 1.59
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw (2014) 1.17
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol (2013) 1.01
The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica (2016) 0.97
Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphoma. Oncologist (2015) 0.95
How to manage mantle cell lymphoma. Leukemia (2014) 0.90
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transplant (2013) 0.89
The misguided ethics of crossover trials. Contemp Clin Trials (2013) 0.89
Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist (2013) 0.89
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood (2014) 0.89
Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant (2014) 0.88
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol (2015) 0.86
Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr (2014) 0.84
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant (2013) 0.84
Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. Haematologica (2014) 0.83
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget (2015) 0.83
Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. Leukemia (2013) 0.83
Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol (2013) 0.82
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma. Biol Blood Marrow Transplant (2014) 0.81
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol (2015) 0.81
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother (2013) 0.80
Management of mantle cell lymphoma in the elderly patient. Clin Interv Aging (2013) 0.79
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma (2014) 0.79
Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol (2013) 0.79
Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. Am J Hematol (2015) 0.78
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biol Blood Marrow Transplant (2016) 0.78
Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol (2014) 0.78
Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report. Oncol Lett (2015) 0.77
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? Bone Marrow Transplant (2015) 0.77
Bortezomib for the treatment of mantle cell lymphoma: an update. Ther Adv Hematol (2016) 0.77
The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience. BMC Infect Dis (2014) 0.77
Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia (2015) 0.77
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? Haematologica (2016) 0.76
Mantle cell lymphoma: observation to transplantation. Ther Adv Hematol (2015) 0.76
Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells. PLoS One (2015) 0.76
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol (2015) 0.76
Haematological cancer: For elderly, R-CHOP and maintain. Nat Rev Clin Oncol (2012) 0.75
Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab. J Investig Med High Impact Case Rep (2017) 0.75
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 0.75
Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year. Ecancermedicalscience (2016) 0.75
Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. Chin J Cancer Res (2016) 0.75
Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia (2016) 0.75
Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant (2016) 0.75
Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma? Contemp Oncol (Pozn) (2014) 0.75
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. World J Transplant (2015) 0.75
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC Cancer (2016) 0.75
Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma. Pharmaceuticals (Basel) (2017) 0.75
Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica (2015) 0.75
How to treat old MCL patients: one size fits it all? Blood (2014) 0.75
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable? Haematologica (2015) 0.75
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. Ther Clin Risk Manag (2015) 0.75
Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. Biol Blood Marrow Transplant (2017) 0.75
Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases. Virchows Arch (2014) 0.75
Current and emerging treatment options for mantle cell lymphoma. Ther Adv Hematol (2017) 0.75
Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma. J Cancer Res Clin Oncol (2013) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer (1997) 8.27
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2005) 7.03
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol (1997) 5.86
Environmental correlates of physical activity in youth - a review and update. Obes Rev (2007) 5.03
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95
Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A (1995) 4.89
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Potential environmental determinants of physical activity in adults: a systematic review. Obes Rev (2007) 3.93
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer (2006) 3.78
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest (2007) 3.58
CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A (2001) 3.54
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res (2003) 3.22
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med (1997) 3.21
Retracted Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med (1995) 2.97
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med (1999) 2.89
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78
Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med (1998) 2.68
Retracted Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 2.64
Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford) (2006) 2.57
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50
LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet (1993) 2.49
Effect of CO(2), O(2), and Light on Photosynthesis and Photorespiration in Wheat. Plant Physiol (1980) 2.48
Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood (2000) 2.39
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2006) 2.38
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol (2000) 2.30
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24
Spontaneous dissection of the celiac artery. Ann Vasc Surg (2001) 2.22
Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med (1999) 2.13
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol (2011) 2.12
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res (2000) 2.09
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08
Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol (1996) 2.05
TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol (1999) 2.05
Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med (2008) 2.05
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol (2012) 2.03
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood (2000) 2.00
Benign notochordal cell tumour: case report. Diagn Interv Imaging (2013) 1.99
Caspase activation is required for terminal erythroid differentiation. J Exp Med (2001) 1.97
Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett (2005) 1.96
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95
A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med (1995) 1.94
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol (1991) 1.94
CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol (1990) 1.93
The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res (1996) 1.93
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci U S A (1998) 1.92
Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today (1997) 1.91
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 1.91
Serological identification of human tumor antigens. Curr Opin Immunol (1997) 1.91
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol (2002) 1.87
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem (1995) 1.86
Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol (1997) 1.86
Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant (2010) 1.86
Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer (1998) 1.82
Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia (2001) 1.82
Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol (2004) 1.79
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia (2004) 1.77
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol (2000) 1.77
Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol (1997) 1.77
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol (1999) 1.76
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia (2006) 1.76
Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol (2007) 1.75
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood (2001) 1.74
Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura. Br J Haematol (1997) 1.71
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia (2006) 1.70
Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab (2002) 1.70